The bioavailability of a pharmaceutical compound is a critical parameter that directly influences its therapeutic efficacy and dosing regimen. This study aimed to assess the bioavailability of paliperidone palmitate nanocapsule a novel drug delivery system by animal study using albino rats. Following a single oral administration of paliperidone palmitate nanocapsule suspension, blood samples were collected at predetermined time points, and plasma concentrations were determined using HPLC analysis. Pharmacokinetic parameters, including maximum plasma concentration (Cmax), time to reach Cmax (Tmax), area under the curve (AUC), apparent volume of distribution (Vd) and mean residence time (MRT) were calculated. The results demonstrated that paliperidone palmitate nanocapsule suspension exhibited favourable bioavailability in comparison to conventional suspension of paliperidone palmitate. The calculated Tmax of 6 hr, Cmax and AUC values were 219 ng/ml and 2086.75ng*hr/L respectively, indicating efficient systemic exposure and sustained drug levels. The comparative bioavailability study of paliperidone palmitate nanocapsule suspension exhibit higher bioavailability compared with conventional paliperidone palmitate suspension. In conclusion, this bioavailability study provides valuable insights into the pharmacokinetic profile of paliperidone palmitate nanocapsule in animal study suggesting its potential as a promising drug candidate with efficient absorption and favourable systemic exposure.